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Characterization of Extracellular
Vesicles Isolated From Human Milk
Using a Precipitation-Based Method
Diana C. Bickmore 1 and John J. Miklavcic 1,2*
1 Food Science and Nutrition, Schmid College of Science and Technology, Chapman University, Orange, CA, United States,
2 School of Pharmacy, Chapman University, Orange, CA, United States
Extracellular vesicles (EV) function in intercellular communication, and those in human
milk may confer immunologic benefits to infants. Methods of EV isolation such as
ultracentrifugation (UC) may not be feasible for the study of EVs in human milk due to the
need for large sample volume. A technique to isolate EVs from a small volume of human
milk using a precipitation reagent is described herein. Electron microscopy, nanoparticle
tracking analysis, and semi-quantitative antibody array were conducted to confirm
isolation of human milk EVs. Count, size, protein content, and fatty acid quantification
of EVs were determined. This isolation technique yielded 8.9 x 109 (± 1.1 × 109) EV
particles/mL of human milk. The present method meets the Minimal Information for
Studies of Extracellular Vesicles (MISEV) guidelines. An established EV isolation method
suitable for a low volume of human milk will facilitate further research in this growing area.
Keywords: breastfeeding, dynamic light scattering, exosome isolation, exosome verification, fatty acids,
nanovesicles, nanoparticle tracking analysis, scanning electron microscopy
INTRODUCTION
It is well-known that consumption of human milk is associated with enhanced infant health
outcomes in comparison to consumption of infant formula. However, it is not fully known which
components of human milk may be responsible for supporting optimal health and development of
newborns. Increasing research suggests that EVs from human milk have physiologic function that
may impact acute and chronic health outcomes. Human milk EVs promote epithelial cell growth
in the intestine (1) and were found to protect intestinal epithelial cells from oxidative stress (2).
Additionally, humanmilk EVs have been implicated in the immunemodulating function of human
milk, and may play a role in the development of the neonatal immune system (3). These effects may
be attributed to the protein, lipid, or microRNA cargo of human milk EVs (3). A reliable method
for consistent isolation of EVs from humanmilk is needed to determine the functional components
of EVs to which enhanced infant health outcomes can be attributed.
Although UC is the most commonly used method to isolate EVs from biospecimens (4), the
feasibility of this method for human milk research is limited. As a precious biofluid for feeding
newborns, acquiring the large volume of human milk needed for EV isolation using UC is not
always feasible. Unfortunately, no method of EV isolation has been authenticated for use with a
low volume of human milk (≤2ml); prior studies have isolated human milk EVs from a starting
volume of 9mL (5). As a result, the limitations in conducting research in this area have created
a knowledge gap. Additionally, authentication of an EV isolation method from low volumes of
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human milk will facilitate research on EVs throughout milk
production periods, the course of lactation, over time-of-
day variation, and perhaps most importantly in low volume
producers, which are not adequately studied.
This limitation has several potential negative consequences.
First, analysis of only large volumes may limit research to
use of pooled human milk. This measure would result in a
greater understanding of average milk composition but not of
interindividual variability. Second, analyses may be limited solely
to time of lactation when higher volumes of milk are produced.
This may then result in a disparate understanding of mature milk
relative to early and transitional milks. Finally, research may be
limited to studies of mothers with high volume ofmilk expression
instead of low volume producers. Therefore, a strong need exists
for a method of isolate EVs from a low volume of human milk.
A novel method for the isolation of EVs requires verification
procedures. The International Society for Extracellular Vesicles
(ISEV) released MISEV guidelines in 2018 (6) detailing the
minimum criteria for confirming isolation of EVs. MISEV
guidelines recommend that each EV preparation be (i) defined
quantitatively by the source of EVs, (ii) characterized to
determine the abundance of EVs by total particle number or
protein/lipid content, (iii) tested for components associated with
EV subtypes or EVs generically, and (iv) tested for the presence
of non-vesicular co-isolated components. This paper describes
a precipitation-based method for the isolation of EVs from
human milk. The subsequent characterization of EVs suggest
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FIGURE 1 | Workflow schematic of EV isolation from human milk using a precipitation-based isolation method.
successful isolation in compliance with the MISEV guidelines.
EVs isolated using the present method are therefore appropriate
for downstream characterization and functional analyses to
better understand the health and immune-modulating properties
of human milk.
METHODS
Mature milk (>6 months after initiation of lactation) was pooled
and pasteurized from donors to develop the EV isolation method
(Prolacta Bioscience, City of Industry CA). Twelve volunteers
also provided samples of expressed milk between 2 and 4
weeks postpartum which were immediately frozen at −80◦C.
Ethics approval was obtained from the Chapman University
Institutional Review Board. The EV isolation method (Figure 1)
outlined herein is adapted from the instructions for a commercial
precipitation reagent (7) and a previously published protocol (8).
EV Isolation Method
Thawing, Defatting, and Removal of Cell Debris
1. Thaw frozen human milk at 4◦C. Once thawed, vortex milk
for∼3 s.
2. If milk was not aliquoted into microcentrifuge tubes prior to
freezing, aliquot 1.5–2mL (or desired volume) human milk
into microcentrifuge tubes.
3. Centrifuge at 2,000× g for 10min to separate and remove the
fat layer with a metal spatula. Discard the fat layer and transfer
Frontiers in Nutrition | www.frontiersin.org 2 March 2020 | Volume 7 | Article 22
Bickmore and Miklavcic Isolation of EVs From Human Milk
milk to a new tube. Removing the fat layer also removes milk
fat globules (9).
4. Centrifuge the defatted milk at 12,000 × g for 30min
to remove cell debris. Transfer milk supernatant and/or
discard pellet.
5. Filter milk supernatant through a 0.45µm cellulose syringe
filter into a newmicrocentrifuge tube to further eliminate cells
and cellular debris.
EV Isolation
6. Using a 5:1 ratio of milk supernatant: ExoQuick-TCTM
reagent (System Biosciences, Palo Alto CA), add reagent to
the filtered milk and gently invert until mixed.
7. Incubate at 4◦C overnight or for at least 12 h.
8. After incubation, centrifuge at 5,000 × g for 30min (beige
pellet will appear at the bottom of the tube).
9. Discard supernatant, and resuspend EV pellet in 100–600µL
PBS (pH 7.4).
10. Depending on downstream application, use resuspended
EVs stored at 4◦C within 3 days or freeze immediately
at−80◦C.
Scanning Electron Microscopy
Zeiss Gemini Sigma 300 scanning electron microscope (SEM)
was used to visualize EVs isolated frommilk expressed at 2 weeks
postpartum (n = 1 volunteer). EVs were visualized 1 day after
they were isolated, resuspended, and stored at 4◦C. The original
EV resuspension in PBS (500 µL) was further diluted in PBS
(1:1,000). SEM slides were prepared with 2 µL of diluted EVs.
Argon gas sputter coating of EVs with 3 nm gold-palladium alloy
was performed to prevent sample destruction.
Nanoparticle Tracking Analysis
Nanoparticle Tracking Analysis (NTA; Nanosight NS01) was
used to determine the concentration and size of EVs isolated from
2 µm  
FIGURE 2 | Image of EVs obtained by SEM from participant (n = 1), Electron
high tension = 5.00 kV, working distance = 20.9mm, detector = secondary
electron, magnification = 8.70K X, vacuum mode = high vacuum, height =
9.851µm.
the pooled milk sample. A sample of EVs originally resuspended
in PBS (500 µL) and frozen at −80◦C was thawed on ice
and further diluted in PBS (1:75) prior to injection. Detection
threshold was set to four, and three runs each of 30 s in duration
were completed and analyzed using NTA 3.1 software. Total yield
(EV particles/mL milk) was calculated based on dilution factors
and a starting volume of 1.5 mL milk.
Dynamic Light Scattering
The diameter of EVs isolated from the pooled milk sample
was measured with a Mobius Dynamic Light Scattering (DLS)
instrument (Wyatt Technology) using DLS Firmware Version
1.2.0.0. Laser wavelength was set to 532 nm, and a detector angle
of 163.5◦ was used. DLS acquisition time was set to 5 s and a
number acquisition of three was used to perform three technical
replications on EVs stored at 4◦C over the course of 10 days.
Exocheck Antibody Array
The ExocheckTM Antibody Array (System Biosciences, Palo Alto
CA) was used according to the manufacturer’s instructions
(10) to determine the presence or absence of common EV
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FIGURE 3 | Diameter and concentration of human milk EVs from pooled
human donor milk measured by NTA. Technical replicates were performed in
triplicate (solid line = trial 1; dashed line = trial 2; dotted line = trial 3) (A) and
the average of the three runs was calculated (B). The above graphs are plotted
from the 10th−90th percentile of EV sizes (22.5–312.5 nm) to exclude particles
which do not meet the size criterion for likely EVs.
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proteins (CD63, EpCAM, Annexin5, TSG101, Flotilin1, ICAM,
ALIX, CD81) in EVs isolated from milk expressed at 4 weeks
postpartum (n= 1 volunteer). Resuspended EVs were thawed on
ice prior to antibody array analysis.
Determination of Total Fatty Acid
Concentration
The EVs fromwhich fatty acids were analyzed were isolated using
2mL aliquots of pooled milk, and with variations in EV isolation
steps. A 5:1 and 10:1 ratio of milk supernatant: ExoQuick-TCTM
reagent was used with or without (0.45µm cellulose) filtration
or purification using ExoQuick-TCTM ULTRA purification
columns according to the manufacturer’s instructions (System
Biosciences, Palo Alto, CA). Prior to fatty acid analysis, EVs were
isolated from the pooled milk sample, resuspended in PBS (500
µL), frozen at −80◦C, and thawed on ice. Fatty acid analysis was
performed by Creative Biostructure (Shirley, NY USA).
The total fatty acid concentration of EVs was determined by
colorimetric analysis in triplicate (n = 1 per isolation variation).
Standards were prepared with palmitic acid (1 nmol/µL).
Samples were diluted and homogenized. Standard dilution (50
µL) or sample (0.5–25 µL) were added to each sample well. The
final volume was adjusted to 50 µL with assay buffer. An acyl-
coenzymeA synthetase reagent (2µL) was added to each reaction
well, mixed, and incubated (20min, 37◦C). Samples were then
incubated (30min, 37◦C) in the dark with reaction mix (2 µL)
containing assay buffer (44 µL), fatty acid probe (2 µL), enzyme
mix (2 µL), and enhancer (2 µL). Finally, optical density was
measured on a microplate reader at 562 nm.
Protein Quantification
A QubitTM 4 Fluorometer was used to measure the protein
concentration in humanmilk EVs isolated frommilk expressed at
2 weeks postpartum (n = 10 volunteers). Resuspended EVs were
thawed on ice prior to protein quantification. The instrument was
calibrated with protein standards according to themanufacturer’s
instructions (11). EV samples originally resuspended in 600 µL
PBS were thawed on ice and diluted in PBS (1:20). Lysis buffer
(10µL) was added and samples were vortexed (Protease Inhibitor
Cocktail, RIPA buffer, Thermo Fisher Scientific, Waltham
MA). Protein concentration was measured in duplicate after
incubating (15min, room temperature) the lysate (1 µL) with
working reagent (199 µL). Protein quantification of EVs was
calculated based on dilution factors and a starting volume of
1.5 mL milk.
RESULTS
SEM (Figure 2), NTA (Figure 3), DLS (Figure 4), and an
antibody array (Figure 5) were used to image, quantify,
measure the average diameter, and identify protein markers
characteristic of EVs. The image obtained by SEM (Figure 2)
revealed the size of nanovesicles in the expected range for
EVs, approximately 50–350 nm. Results from analysis by NTA
(Figure 3, Supplementary Figure 1, Video 1) revealed that the
isolation method yielded 8.9 × 109 (± 1.1 × 109) particles/mL
of human milk. The mean and mode diameter of EVs were 179.3
and 150.3 nm, respectively (Figure 3). No standard deviation
is reported for the mean since a trimodal distribution of
EV populations was observed. Results from DLS (Figure 4)
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FIGURE 4 | Average diameter of EVs from pooled human donor milk measured for 10 consecutive days after isolation and storage at 4◦C. Error bars were excluded
because individual standard deviations were <5% of the mean. Pooled SD = 33.45.
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showed that the average diameter of EVs 1 day after isolation
was 213.6, and 249.7 nm 10 days after isolation. Error bars
for individual days were excluded because individual standard
deviations for technical replicates were <5% of the mean.
Antibody array (Figure 5) indicated that the sample was
positive for the following known EV markers: cluster of
differentiation 81 (CD81), ALG-2-interacting Protein X (ALIX),
intracellular adhesion molecule (ICAM), tumor susceptibility
gene 101 (TSG101), and Annexin5, and negative for cluster
of differentiation 63 (CD63), epithelial cell adhesion molecule
(EpCAM), and flotilin1.
After verification of isolation, human milk EVs were
characterized by quantifying total fatty acids (Figure 6) and
protein concentration (Table 1). The average total fatty acid
concentration of EVs isolated with the recommended method
(5:1, filter, no column purification) was 36.94 mg/dL. The
mean protein concentration of human milk EVs was 5.08
(±0.15) mg/dL.
DISCUSSION
The method of EV isolation from human milk described herein
meets the MISEV criteria (6) for verifying the presence of EVs.
EVs isolated with the proposed method were (i) quantified
CD 63
EpCAM
Annexin5
TSG101
Blank
PC
PC
GM130
Flotilin1
ICAM
ALIX
CD81
FIGURE 5 | Antibody array of human milk EVs from participant (n = 1). PC
represents the positive control, and GM130 is a cellular contamination marker.
CD 63 = cluster of differentiation 63, EpCAM = epithelial cell adhesion
molecule, TSG101 = tumor susceptibility gene 101, ICAM = intracellular
adhesion molecule, ALIX = ALG-2-interacting Protein X, CD81 = cluster of
differentiation 81.
in relation to the source of human milk, (ii) characterized
to determine the abundance of EVs by total particle number
and lipid & protein content, (iii) tested for the presence of
markers associated with EVs, and (iv) tested for the presence
of non-vesicular co-isolated components. The method adapted
from manufacturer instructions for a precipitation reagent
(7) and previous literature (8) was shown to be suitable to
adequately characterize EVs isolated from human milk and for
downstream applications.
There is consistency between the average EV diameter
measured by SEM, NTA, and DLS (Figures 2–4). Unlike NTA
which generates size distribution data, DLS measures the average
particle diameter. Measurement by DLS then may be skewed
by low concentrations of outliers or clustering of particles (12).
Therefore, the ∼15% difference in diameter between SEM, NTA,
and DLS measurements could be due to overestimation of
diameter by DLS. The recommended method presented herein
yielded 8.9× 109 (± 1.1× 109) EV particles/mL of human milk.
Another group isolated human milk EVs and reported a yield of
8.0× 1010 particles/ml of milk using a UC based method (5). The
difference in yield could be attributed to the fact that banked,
pasteurized milk was used in the present method. Additionally,
EVs were frozen and thawed prior to quantification without
defatting before initial freezing, which has shown the decreased
recovery of EVs (3).
In the MISEV guidelines, it is recommended that operational
terminology for extracellular vesicles based on factors such as size
be used. EVs <200 nm in diameter would be considered “small,”
and EVs >200 nm considered medium or large (6). Results from
NTA indicated that the greatest concentration of particles is
around 153 nm (Figure 3), meaning the EV population in highest
abundance would be classified as small. The 10th−90th percentile
of particle size were graphed (Figure 3), as particles outside this
range were likely aggregates or fragments.
Because storage conditions may affect EV characterization,
MISEV guidelines indicate the importance of describing storage
conditions such as storage container, temperature, buffer, freeze-
thaw cycles of biofluid and EVs, etc. (6). It was previously
found even that storage of EVs for 2 h at 4◦C decreased the
viability of the exosome population, but the change in size
was not measured (3). The timecourse experiment (Figure 4)
represents storage-induced changes in diameter starting from
freshly isolated EVs measured over the course of 10 days. The
average diameter of EVs measured by DLS increased over time
after isolation and storage. This may indicate swelling and
enlargement of EVs, or aggregation of particles. Therefore, when
performing studies to determine the relation between structure
and function, it may be advantageous to use EVs immediately
after isolation.
For protein-based verification of EV isolation, MISEV
guidelines stipulate that at least one type of protein in
two broad categories should be positively identified and the
absence of one negative marker indicated. These categories
include transmembrane or GPI-anchored proteins, such as
the tetraspanins CD63 and CD81, and EV-recovered cytosolic
proteins such as ALIX and flotillins-1 and 2. To verify the absence
of non-EV isolated co-structures, markers such as albumin can
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FIGURE 6 | Total fatty acid concentration of EVs isolated from pooled human donor milk. The ratios represent the proportion of milk supernatant: ExoQuick-TCTM
reagent used during isolation. Milk was either filtered (0.45µm) prior to EV isolation or EVs isolated were purified by column affinity after isolation. Error bars were
excluded because individual standard deviations for two technical replicates were <5% of the mean. Pooled SD = 18.78.
TABLE 1 | Protein concentration of EVs isolated from human milk (n = 10).
Sample Protein content
(mg/dL milk)
1 5.20
2 5.00
3 5.11
4 5.02
5 5.15
6 5.18
7 5.24
8 4.98
9 5.20
10 4.75
Mean 5.08
SD 0.15
For each sample, technical replicates were performed in duplicate.
be used (6). The antibody array (Figure 5) verified that human
milk EVs isolated were positive for proteins in the tetraspanin
and EV-recovered cytosolic proteins category, and also negative
for cellular contamination marker.
The amount of exosomal protein has been used as a means
of EV quantification (13). Considering that the average protein
concentration measured in EVs was 5.08 mg/dL, EV protein
comprises ∼0.42% of total protein from mature human milk,
assuming the protein concentration of mature human milk is
∼1,200 mg/dL (14). However, it should be noted that protein
quantification with biofluids such as human milk may not be
a consistent and reliable method of quantification due to the
presence of co-isolated molecules. Therefore, we reported the
total fatty acid concentration of human milk EVs (Figure 6).
Based on the assumption that fat content of human milk is
primarily in the form of triglyceride, we estimated that EV
fatty acids are ∼0.8% of total fatty acids in mature human
milk (14).
We compared fatty acid quantification among EVs isolated
from human milk with different volumes of reagent, use of size
exclusion filter, and with or without column affinity purification.
We suggest a supernatant-to-precipitation reagent ratio of 5:1
for optimal yield of EVs to quantify fatty acids. We also
suggest filtration of milk by size exclusion after defatting to
remove non-EV artifacts such as casein and cellular debris.
However, it is unclear whether column affinity purification after
EV isolation performs similarly to size exclusion filtration of
milk supernatant prior to EV isolation. Although fatty acid
quantification was similar after each method, it is unknown
if filtration and purification result in differences in the EV
populations isolated.
The present method of isolating EVs from human milk
fulfills the MISEV criteria by characterizing the EVs with
quantitative and qualitative methods, confirming the presence of
characteristic EVmarkers, and confirming (Figure 5) the absence
of non-EV components. The application of this isolation method
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extends beyond the applications detailed in our manuscript. The
ability to successfully isolate EVs from small volumes of human
milk can be applied to miRNA isolation, proteomics, lipidomics,
and functional in vitro assays.
CONCLUSIONS
EVs were successfully isolated from human milk using a
precipitation reagent. The method yielded 8.9 × 109 ± 1.1 ×
109 EV particles/mL of human milk. Protein and fatty acid
concentration of EVs in human milk were determined and the
percentage of fatty acids and protein in EVs relative to the
whole milk were ∼0.8% and ∼0.42%, respectively. The method
presented is consistent and reliable for isolating, quantifying,
and characterizing human milk EVs for research and clinical
purposes and in continuing to understand the human milk
food matrix. As a dynamic food and biofluid, future study may
elucidate how EVs vary over i) early, transitional and mature
milk production periods, ii) course of lactation (fore vs. hind
milk), and iii) time-of-day variation. This method can be used
to elucidate the role of human milk EVs in neonatal health and
immune system development, and for applications of formula
and human milk fortifier production.
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